Preliminary observations on short-course chemotherapy in tuberculous serositis.
Short-course chemotherapy has not been previously assessed in tuberculous serositis. In this study, 18 patients with tuberculous serositis were studied. 600 mg of rifampicin, 300 mg of isoniazid and 25 mg of pyridoxine were given daily for 6 months. 14 patients completed the therapeutic regimen and were evaluated. 11 of these showed excellent results on the long-term follow-up (18-24 months) and 3 of shorter-term follow-up (9-12 months). Short-course chemotherapy appears to be efficacious in the treatment of tuberculous serositis. However, further and larger trials are recommended.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011733:Pyridoxamine / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D012700:Serositis / Q000188:drug therapy*; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy*
D011733:Pyridoxamine; D007538:Isoniazid; D012293:Rifampin